Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for ...

Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy ...

Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past ...

Novo Nordisk has launched the first once-daily GLP-1 weight-loss pill, an oral version of Wegovy approved by the FDA last month. Clinical trials showed the Wegovy pill delivered average weight ...

If you've been following the weight-loss medication revolution, you've likely heard about Wegovy injections. But now there's a new option that might be even more appealing: a once-daily pill. The ...

US has gone into a peptide craziness as Wegovy pill reaches 2 million prescriptions since its January launch, per Novo ...

Novo Nordisk shares climbed Wednesday after the Danish drugmaker beat estimates with its latest quarterly results.

GLP-1 shots and pills both help regulate appetite and blood sugar. Learn the differences in effectiveness, cost, and who ...

Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the ‌U. in the fourth week, a modest uptake ...